TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive experience in raising capital and corporate strategy, and his expertise is well-suited to support the company’s focus on advancing the delivery of psychedelic medicines. Currently managing director at 21 Corporate, an Australia-based corporate advisory firm, Ntoumenopoulos is also a strategic investment adviser at Freeman Road, an investment group specializing in health and early-stage medtech companies. Ntoumenopoulos is also a director at Race Oncology and ResApp Diagnostics, a respiratory diagnostic company. “Chris is a seasoned, mission-driven advisor who supports organizations to excel beyond development and commercialization challenges,” said Tryp Therapeutics interim CEO and chief scientific officer Jim Gilligan in the press release. “He brings both financial and biotech experience as well as a global perspective to the Tryp team. His appointment is a milestone in Tryp's growth strategy and mission to fulfill the vast demand for innovative health solutions for underserved indications.”
To view the full press release, visit https://ibn.fm/ewEHV
About Tryp Therapeutics Inc.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-for-Neuropsychiatric-Disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at http://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.